TP53 mutations in human cancers: origins, consequences, and clinical use.

Olivier, M., Hollstein, M., Hainaut, P.·2010·Cold Spring Harbor Perspectives in Biology
DOI 10.1101/cshperspect.a001008

Cited by (1,002)

Items 801–900 of 1,002

  1. Molecular Targets in Salivary Gland Cancers: A Comprehensive Genomic Analysis of 118 Mucoepidermoid Carcinoma Tumors
    Maroun Bou Zerdan, Prashanth Ashok Kumar, Daniel J. Zaccarini, Jeffrey S. Ross, Richard S.P. Huang, Abirami Sivapiragasam · 2023 · Biomedicines
  2. The dual role of p63 in cancer
    Yongfeng Xu, Xiaojuan Yang, Qunli Xiong, Junhong Han, Qing Zhu · 2023 · Frontiers in Oncology
  3. The Role of Bcl‐2 Family Proteins and Sorafenib Resistance in Hepatocellular Carcinoma
    Alex José de Melo Silva, Juliana Ellen de Melo Gama, Sheilla Andrade de Oliveira · 2024 · International Journal of Cell Biology
  4. Current insights and future directions of Li-Fraumeni syndrome
    Mohammad‐Salar Hosseini · 2024 · Discover Oncology
  5. PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer Treatment
    Navneet Sharma, Akash Bhati, Shagun Aggarwal, Kamal Shah, Hitesh Kumar Dewangan · 2024 · Current Pharmaceutical Design
  6. TP53 Aberrations in Chronic Lymphocytic Leukemia
    Martin Trbušek, Jitka Malčíková · 2013 · Advances in experimental medicine and biology
  7. TP53 gene polymorphism: Importance to cancer, ethnicity and birth weight in a Brazilian cohort
    Helena Strelow Thurow, Ricardo Haack, Fernando Pires Hartwig, Isabel O. Oliveira, Odir Antônio Dellagostin, Denise Petrucci Gigante, Bernardo Lessa Horta, Tiago Veiras Collares, Fabiana K. Seixas · 2011 · Journal of Biosciences
  8. Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts
    Annette M. Krais, Karl–Rudolf Muehlbauer, Jill E. Kucab, Helena Chinbuah, Michael G. Cornelius, Quan-Xiang Wei, Monica Hollstein, David H. Phillips, Volker Manfred Arlt, Heinz H. Schmeiser · 2014 · Toxicology in Vitro
  9. The p53/mouse double minute 2 homolog complex deregulation in merlin‐deficient tumours
    Sylwia Ammoun, Marei Caroline Schmid, Lu Zhou, David A. Hilton, Magdalena Barczyk, Clemens Oliver Hanemann · 2014 · Molecular Oncology
  10. Rats deficient for p53 are susceptible to spontaneous and carcinogen-induced tumorigenesis
    Hengxiu Yan, Hongmei Wu, C. Ashton, C. Tong, Qi‐Long Ying · 2012 · Carcinogenesis
  11. Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine
    María Jesús Álvarez-Cubero, Luis Javier Martínez-González, Inmaculada Robles‐Fernandez, José Fabián Martínez‐Herrera, G. Garcia-Rodriguez, Manrique Pascual-Geler, Jose M. Cozar, Jose Antonio Lorente · 2016 · Molecular Diagnosis & Therapy
  12. Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma
    Kenzo Ohara, Takayuki Ohkuri, Takumi Kumai, Toshihiro Nagato, Yui Nozaki, Kei Ishibashi, Akemi Kosaka, Marino Nagata, Shohei Harabuchi, Mizuho Ohara et al. · 2018 · OncoImmunology
  13. Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity
    Nicholas William Fischer, Aaron Prodeus, Jean Gariépy · 2018 · JCI Insight
  14. High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer
    Seung Eun Lee, Hye Seung Lee, Kyoung-Yeon Kim, Jung‐Hoon Park, Hanseong Roh, Ha Young Park, Wan Seop Kim · 2019 · Scientific Reports
  15. Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer
    S. Kwon, A. Budhu, H. Woo, Jittiporn Chaisaingmongkol, Hien Dang, M. Forgues, C. C. Harris, Gao Zhang, Noam Auslander, Eytan Ruppin et al. · 2019 · Scientific Reports
  16. Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients
    Ruirui Jiang, Bo Zhang, Xiaodong Teng, Peizhen Hu, Sanpeng Xu, Zuyu Zheng, Rui Liu, Tingdong Tang, Feng Ye · 2020 · Scientific Reports
  17. Molecular Biomarkers in Colorectal Carcinoma
    Elena Puerta-García, Marisa Cañadas‐Garre, Miguel Ángel Calleja‐Hernández · 2015 · Pharmacogenomics
  18. p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy
    Christie Rodriguez-Ramirez, Jacques Eduardo Nor · 2018 · Critical Reviews™ in Oncogenesis
  19. Integrating multi-omics and machine learning survival frameworks to build a prognostic model based on immune function and cell death patterns in a lung adenocarcinoma cohort
    Yiluo Xie, Huili Chen, Mei Tian, Ziqang Wang, Luyao Wang, Jing Zhang, Xiaojing Wang, Chaoqun Lian · 2024 · Frontiers in Immunology
  20. Genome-Wide Small RNA Sequencing Identifies MicroRNAs Deregulated in Non-Small Cell Lung Carcinoma Harboring Gain-of-Function Mutant p53
    Arindam Datta, Pijush K. Das, Sanjib Dey, Sangeeta Ghuwalewala, Dishari Ghatak, Sk. Kayum Alam, Raghunath Chatterjee, Susanta Roychoudhury · 2019 · Genes
  21. Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis
    Surinder M. Soond, Lyudmila V. Savvateeva, Vladimir A. Makarov, Neonila V. Gorokhovets, Paul A. Townsend, Andrey A. Zamyatnin · 2020 · Cancers
  22. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor
    Zih‐Yin Lai, Kai-Yun Tsai, Shing‐Jyh Chang, Yung‐Jen Chuang · 2021 · International Journal of Molecular Sciences
  23. Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies
    Baixin Ye, Yuping Sheng, Mingming Zhang, Yongxian Hu, He Huang · 2022 · Cancer Letters
  24. Cytotoxic Cyclotides from Anchietea pyrifolia, a South American Plant Species
    Antonio F. Bobey, Meri Emili F. Pinto, Larissa Costa de Almeida, Bibiana Monson de Souza, Nathalia Baptista Días, Juliana de Paula‐Souza, Eduardo Maffud Cilli, Norberto Peporine Lopes, Letícia Veras Costa-Lotufo, Mário Sérgio Palma et al. · 2022 · Journal of Natural Products
  25. Inhibition of GABAA receptors in intestinal stem cells prevents chemoradiotherapy-induced intestinal toxicity
    Cuiyu Zhang, Yu‐Ping Zhou, Junjie Zheng, Nannan Ning, Haining Liu, Wenyang Jiang, Xin Yu, Kun Mu, Yan Li, Wei Guo et al. · 2022 · The Journal of Experimental Medicine
  26. Integration of network pharmacology and intestinal flora to investigate the mechanism of action of Chinese herbal Cichorium intybus formula in attenuating adenine and ethambutol hydrochloride-induced hyperuricemic nephropathy in rats
    Na Li, Mukaram Amatjan, Pengke He, Boheng Zhang, Xianyan Mai, Qianle Jiang, Haochen Xie, Xiaoni Shao · 2022 · Pharmaceutical Biology
  27. Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (TP53) upon Hotspot Mutation p53 Arg248 by Comparative Computational Approach
    Ambritha Balasundaram, C. George Priya Doss · 2022 · International Journal of Molecular Sciences
  28. TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study
    Yuting Tao, Xia Li, Yushan Zhang, Liangyu He, Qinchen Lu, Yaobang Wang, Li-Xin Pan, Zhenxing Wang, Chao Feng, Yuanliang Xie et al. · 2022 · Frontiers in Genetics
  29. The Prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in Prostate Cancer Treatment
    Jian‐Xuan Sun, Ye An, Jia-Cheng Xiang, Jin‐Zhou Xu, Jia Hu, Shaogang Wang, Qi‐Dong Xia · 2023 · International Journal of Molecular Sciences
  30. Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer
    Artūras Dobilas, Yilun Chen, Christian Brueffer, Pia Leandersson, Lao H. Saal, Christer Borgfeldt · 2023 · Cancer Genomics & Proteomics
  31. A noncanonical IRAK4-IRAK1 pathway counters DNA damage–induced apoptosis independently of TLR/IL-1R signaling
    Yuanyuan Li, Richa B. Shah, Samanta Sarti, Alicia L. Belcher, Brian J. Lee, Andrej Gorbatenko, Francesca Nemati, Honglin Yu, Zoe Stanley, Mahbuba Rahman et al. · 2023 · Science Signaling
  32. Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors
    Yizhu Li, Priyanka Saini, Anusha Sriraman, Matthias Dobbelstein · 2015 · Oncotarget
  33. Metabolic sensing by p53: Keeping the balance between life and death
    Genrich V. Tolstonog, Wolfgang Deppert · 2010 · Proceedings of the National Academy of Sciences
  34. Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer
    Jisela Dimas-González, Vilma Maldonado Lagunas, José Díaz‐Chávez, María Eugenia López‐Arellano, JOSÉ GUADALUPE MUÑOZ-CAMACHO, Marco Antonio Terán-Porcayo, Alfredo Lagunas-Martínez · 2017 · Oncology Reports
  35. p53β: a new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median follow-up
    Haiyang Zhang, Yong Zhao, Peng Sun, Miaoqing Zhao, Zhenhui Su, Xunbo Jin, Wei Song · 2018 · Carcinogenesis
  36. Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
    Marica Garziera, Erika Cecchin, Vincenzo Canzonieri, Roberto Sorio, Giorgio Giorda, Simona Scalone, Elena De Mattia, Rossana Roncato, Sara Gagno, Elena Poletto et al. · 2018 · International Journal of Molecular Sciences
  37. Effective treatment of a platinum‑resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition
    Carlo Capalbo, Francesca Belardinilli, Marco Filetti, Claudia Parisi, Marialaura Petroni, Valeria Colicchia, Alessandra Tessitore, Matteo Santoni, Anna Coppa, Giuseppe Giannini et al. · 2018 · Molecular and Clinical Oncology
  38. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients
    Cristina Fortuño, Tina F. Pesaran, Jill S. Dolinsky, Amal Yussuf, Kelly McGoldrick, Pik Fang Kho, Paul Andrew James, Amanda B. Spurdle · 2019 · Cancer Genetics
  39. The Concomitant Expression of Human Endogenous Retroviruses and Embryonic Genes in Cancer Cells under Microenvironmental Changes is a Potential Target for Antiretroviral Drugs
    Alessandro Giovinazzo, Emanuela Balestrieri, Vita Petrone, Ayele Argaw-Denboba, Chiara Cipriani, Martino Tony Miele, Sandro Grelli, Paola Sinibaldi Vallebona, Claudia Matteucci · 2019 · Cancer Microenvironment
  40. Evaluation of circulating cell‑free DNA as a molecular monitoring tool in patients with metastatic cancer
    Clemens Hufnagl, Michael Leisch, Lukas Weiß, Thomas Melchardt, Martin Moik, Daniela Asslaber, Roland Geisberger, Philipp A. Steininger, Thomas Meißnitzer, Daniel Neureiter et al. · 2019 · Oncology Letters
  41. Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors
    Iris Scherwitzl, Silvana Opp, Alicia M. Hurtado, Christine L. Pampeno, Cynthia A. Loomis, Kasthuri S. Kannan, Minjun Yu, Daniel Meruelo · 2020 · Molecular Therapy — Oncolytics
  42. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact ofTP53mutations in breast CA
    Xuerui Li, Xiaoqing Chen, Lingzhu Wen, Yulei Wang, Bo Chen, Yunlian Xue, Liping Guo, Ning Liao · 2020 · Thoracic Cancer
  43. The head and neck cancer genome in the era of immunotherapy
    Neil Ari Wijetunga, Yao Yu, Luc G.T. Morris, Nancy Y. Lee, Nadeem Riaz · 2020 · Oral Oncology
  44. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells
    Amr M. Ghaleb, Malik Padellan, Natalia D. Marchenko · 2020 · Breast Cancer Research
  45. The actin nucleation factors JMY and WHAMM enable a rapid Arp2/3 complex-mediated intrinsic pathway of apoptosis
    Virginia L. King, Nathan K. Leclair, Alyssa M. Coulter, Kenneth G. Campellone · 2021 · PLoS Genetics
  46. Molecular analysis of 10 pleomorphic rhabdomyosarcomas reveals potential prognostic markers and druggable targets
    Zachary L. Chelsky, Vera Paulson, Eleanor Y. Chen · 2021 · Genes Chromosomes and Cancer
  47. Numb exon 9 inclusion regulates Integrinβ5 surface expression and promotes breast cancer metastasis
    Yangjing Zhang, Sascha E. Dho, Kamal Othman, Craig D. Simpson, Jessica Lapierre, Andrew Bondoc, C. Jane McGlade · 2022 · Oncogene
  48. Extracellular Matrix-Based Gene Expression Signature Defines Two Prognostic Subtypes of Hepatocellular Carcinoma With Different Immune Microenvironment Characteristics
    Hui Jun Tang, Tingting You, Zhao Sun, Chunmei Bai, Yingyi Wang · 2022 · Frontiers in Molecular Biosciences
  49. Hyperactivating p53 in Human Papillomavirus-Driven Cancers: A Potential Therapeutic Intervention
    Yusuf M. Idres, Nigel A.J. McMillan, Adi Idris · 2022 · Molecular Diagnosis & Therapy
  50. Characterization of the tilapia p53 gene and its role in chemical-induced apoptosis
    Weijun Mai, Peng Liu, Weina Wang · 2012 · Biotechnology Letters
  51. The presence of the intron 3 16 bp duplication polymorphism ofp53(rs17878362) in breast cancer is associated with a low Δ40p53:p53 ratio and better outcome
    Brianna C. Morten, Michelle W. Wong‐Brown, Rodney John Scott, Kelly A. Avery‐Kiejda · 2015 · Carcinogenesis
  52. p53 Replacement Therapy for Cancer
    Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara · 2016 · Recent results in cancer research/Recent Results in Cancer Research
  53. Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model
    Ramesh T. Gunaratna, Andres Santos, Linjie Luo, Chandandeep S. Nagi, Isabel U. Lambertz, Madison E. Spier, Claudio Jorge Conti, Robin Fuchs‐Young · 2019 · Oncogene
  54. Endocrine Tumors Associated with Neurofibromatosis Type 1, Peutz-Jeghers Syndrome and Other Familial Neoplasia Syndromes
    Esra Kalkan, Steven Gerard Waguespack · 2013 · Frontiers of hormone research
  55. P53 protein and the diseases in central nervous system
    Li Lei, Qixiong Lu, MA Gui-fang, Tao Li, Jiahong Deng, Weijia Li · 2023 · Frontiers in Genetics
  56. Structural basis of bacterial effector protein azurin targeting tumor suppressor p53 and inhibiting its ubiquitination
    Jianjian Hu, Wenxue Jiang, Jiaqi Zuo, Dujuan Shi, Xiaoqi Chen, Xiao Yang, Wenhui Zhang, Lixin Ma, Zhu Liu, Qiong Xing · 2023 · Communications Biology
  57. Integration of deep learning with Ramachandran plot molecular dynamics simulation for genetic variant classification
    Benjamin Tam, Zixin Qin, Bojin Zhao, San Ming Wang, Chon Lok Lei · 2023 · iScience
  58. Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer
    Diego Claro de Mello, Kelly Cristina Saito, Marcella Maringolo Cristovão, Edna Teruko Kimura, César Seigi Fuziwara · 2023 · International Journal of Molecular Sciences
  59. Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma
    Yang Zheng, Heling Peng, Hu Xu, Yong Ou, Dong Wang, Han Wang, Shangqing Ren · 2023 · Frontiers in Pharmacology
  60. From cancer big data to treatment: Artificial intelligence in cancer research
    Mohd Danishuddin, Shawez Khan, Jong-Joo Kim · 2023 · The Journal of Gene Medicine
  61. Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression
    Ashwini Jambhekar, Emily E. Ackerman, Berk A. Alpay, Galit Lahav, Scott B. Lovitch · 2024 · Blood Neoplasia
  62. Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients
    Damien Vasseur, Ahmadreza Arbab, Fabiola Giudici, Christophe Marzac, Stefan Michiels, Marco Tagliamento, Arnaud Bayle, Cristina Smolenschi, Madona Sakkal, Mihaela D. Aldea et al. · 2024 · npj Precision Oncology
  63. Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant
    Dafei Chai, Junhao Wang, Chunmei Fan, Jing Ming Lim, Xu Wang, Praveen Kumar Neeli, Xinfang Yu, Ken H. Young, Yong Li · 2024 · Journal of Hematology & Oncology
  64. Li-Fraumeni Syndrome: Imaging Features and Guidelines
    Babina Gosangi, Irene Dixe de Oliveira Santo, Abhishek R. Keraliya, Y Wang, David Victor Kumar Irugu, Richard Thomas, Ashish Khandelwal, Ami N. Rubinowitz, Anna Shlionsky Bader · 2024 · Radiographics
  65. Mutational profile of TP53 in esophageal squamous cell carcinoma associated with chagasic megaesophagus
    Croider Franco Lacerda, Adriana Cruvinel‐Carloni, Antônio Talvane Torres de Oliveira, Cristovam Scapulatempo‐Neto, Rossana Veronica Mendoza López, Eduardo Crema, Sheila Jorge Adad, Maria Aparecida Marchesan Rodrigues, Maria Aparecida Coelho Arruda Henry, Denise Peixoto Guimarães et al. · 2017 · Diseases of the Esophagus
  66. Systematic Inspection of the Clinical Relevance of TP53 Missense Mutations in Gastric Cancer
    SeongRyeol Moon, Curt Balch, Sungjin Park, Jinhyuk Lee, Ji‐Yong Sung, Seungyoon Nam · 2018 · IEEE Transactions on Computational Biology and Bioinformatics
  67. The Role of Chromosome Deletions in Human Cancers
    Mei Chen, Yi Yang, Yu Liu, Chong Chen · 2018 · Advances in experimental medicine and biology
  68. RETRACTED: Selective killing of human breast cancer cells by the styryl lactone (R)-goniothalamin is mediated by glutathione conjugation, induction of oxidative stress and marked reactivation of the R175H mutant p53 protein
    Surendra Reddy Punganuru, Hanumantha Rao Madala, Viswanath Arutla, Kalkunte S. Srivenugopal · 2018 · Carcinogenesis · Retracted
  69. The Cajal Body Protein WRAP53β Prepares the Scene for Repair of DNA Double-Strand Breaks by Regulating Local Ubiquitination
    Sofie Bergstrand, Eleanor M. O’Brien, Marianne Farnebo · 2019 · Frontiers in Molecular Biosciences
  70. Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non–Small-Cell Lung Cancer
    Nasha Zhang, Jia Wu, Jinming Yu, Hui Zhu, Ming Yang, Ruijiang Li · 2019 · Clinical Lung Cancer
  71. Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
    Elisena Franzese, Sara Centonze, Anna Diana, Angela Lombardi, Francesca Carlino, Luigi Pio Guerrera, Ferdinando De Vita, Michele Caraglia, Sandro Pignata, Fortunato Ciardiello et al. · 2019 · Frontiers in Oncology
  72. The lag effect of exposure to PM2.5 on esophageal cancer in urban-rural areas across China
    Peng Li, Xiya Guo, Jing Jing, Wenbiao Hu, Wenqiang Wei, Xin Qi, Guihua Zhuang · 2021 · Environmental Science and Pollution Research
  73. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
    Dejun Zeng, Zhengyang Hu, Yanjun Yi, Valeria Besskaya, Guangyao Shan, Zhencong Chen, Cheng Zhan, Miao Lin, Zongwu Lin, Qun Wang · 2021 · BMC Pulmonary Medicine
  74. Highly sensitive and quantitative biodetection with lipid-polymer hybrid nanoparticles having organic room-temperature phosphorescence
    Do Hyun Kang, Yingying Zeng, Muneesh Tewari, Jinsang Kim · 2021 · Biosensors and Bioelectronics
  75. BIRC2–BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia
    Khashayar Roohollahi, Yvonne de Jong, Govind M. Pai, Mohamad Amr Zaini, Klaas de Lint, Daoud Sie, Martin A. Rooimans, Davy Rockx, Elizabeth E. Hoskins, Najim Ameziane et al. · 2022 · Scientific Reports
  76. Gene Regulation by p53 in Human Cancer System
    Supratit Ghosh, Meghna Bhattacharjee, Nandan Kumar Jana · 2022 · Asian Pacific Journal of Cancer Biology
  77. Interplay between p53-family, their regulators, and PARPs in DNA repair
    Shahin Emami · 2010 · Clinics and Research in Hepatology and Gastroenterology
  78. Capture‐based next‐generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing
    Jing Xie, Xiongxiong Lu, Xue Wu, Xiaoyi Lin, Chao Zhang, Xiaofang Huang, Zhili Chang, Xinjing Wang, Chenlei Wen, Xiaomei Tang et al. · 2016 · Molecular Genetics & Genomic Medicine
  79. Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?
    Bhakti Basu, Sandip Kanti Basu · 2016 · Cancer Biotherapy and Radiopharmaceuticals
  80. Association of p53 codon72 Arg>Pro polymorphism with susceptibility to nasopharyngeal carcinoma: evidence from a case–control study and meta-analysis
    Suman Kumar Sahu, Sudipta Chakrabarti, S D Roy, Nizara Baishya, R. Rajendra Reddy, Sujit Suklabaidya, A Kumar, Suchitra Mohanty, Santanu Maji, A Suryanwanshi et al. · 2016 · Oncogenesis
  81. Acquisition of cancer stem cell-like properties in human small airway epithelial cells after a long-term exposure to carbon nanomaterials
    Chayanin Kiratipaiboon, Todd A. Stueckle, Rajib Ghosh, Liying Wang Rojanasakul, Yi Chen, Cerasela Zoica Dinu, Yon Rojanasakul · 2019 · Environmental Science Nano
  82. Towards a Better Understanding of the Relationships between Galectin-7, p53 and MMP-9 during Cancer Progression
    Yves St‐Pierre · 2021 · Biomolecules
  83. Liquid chromatography
    Vaneet Kumar Sharma · 2012
  84. Genomic landscape and preclinical models of angiosarcoma
    Annaleigh Benton, Bozhi Liu, Lauren E. Gartenhaus, Jason A. Hanna · 2024 · Molecular Oncology
  85. From experimental studies to computational approaches: recent trends in designing novel therapeutics for amyloidogenesis
    Pooja Ghosh, Agnibin Kundu, Debabani Ganguly · 2024 · Journal of Materials Chemistry B
  86. OTUD7B is a new deubiquitinase targeting p53
    Chaopu Ding, Leixi Cao, Ruijie Wang, Qiong Wu, Mengfan Li, Jinjing Zhang, Rick Francis Thorne, Jinming Li, Jianli Ma, Mian Wu et al. · 2025 · Theranostics
  87. Synergistic Targeting of EGFR, ESR1, BCL2, and TP53 Pathways: A Multi-Pronged Approach for Advanced Breast Cancer Therapy
    Harneet Marwah, Hitesh Kumar Dewangan · 2025 · Current Cancer Drug Targets
  88. AARS1 and AARS2: From Protein Synthesis to Lactylation-Driven Oncogenesis
    Lingyue Gao, Jihua Guo, Rong Jia · 2025 · Biomolecules
  89. The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy
    Muhammad Tufail, Kunxiang Gong, Bushra Ijaz, Harsh H. Patel, Weng‐Onn Lui, Xiumei Wang, Jie Li · 2026 · Drug Resistance Updates
  90. Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
    Muqi Shi, Yan Wang, Weidong Tang, Xiaohong Cui, Han Jiang Wu, Yijie Tang, Peng Wang, Wei Wu, Haijian Zhang · 2020 · Annals of Translational Medicine
  91. Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
    Won Gun Kwack, So Youn Shin, Seung Hyeun Lee · 2020 · OncoTargets and Therapy
  92. Exploiting GRK2 Inhibition as a Therapeutic Option in Experimental Cancer Treatment: Role of p53-Induced Mitochondrial Apoptosis
    Jessica Gambardella, Antonella Fiordelisi, Gaetano Santulli, Michele Ciccarelli, Federica Andrea Cerasuolo, Marina Sala, Eduardo Sommella, Pietro Campiglia, Maddalena Illario, Guido Iaccarino et al. · 2020 · Cancers
  93. Prioritizing genes for systematic variant effect mapping
    Da Kuang, Rebecca Truty, Jochen Weile, Britt A. Johnson, Keith Nykamp, Carlos L. Araya, Robert Luke Nussbaum, Frederick P. Roth · 2020 · Bioinformatics
  94. Natural Merosesquiterpenes Activate the DNA Damage Response via DNA Strand Break Formation and Trigger Apoptotic Cell Death in p53-Wild-Type and Mutant Colorectal Cancer
    Apisada Jiso, Philipp Demuth, Madeleine Bachowsky, Manuel Haas, Nina Seiwert, Daniel Heylmann, Birgit Rasenberger, Markus Christmann, Lea Dietrich, Thomas Brunner et al. · 2021 · Cancers
  95. Mutant p53-microRNA-200c-ZEB2-Axis-Induced CPT1C Elevation Contributes to Metabolic Reprogramming and Tumor Progression in Basal-Like Breast Cancers
    Chen-Yun Wang, Cing-Hong Wang, Ru-Tsun Mai, Ting-Wen Chen, Chia-Wei Li, Chi-Hong Chao · 2022 · Frontiers in Oncology
  96. TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects
    Mohana Eswari Ragu, Joanna Lim, Pei-Sze Ng, Cheng Har Yip, Pathmanathan Rajadurai, Soo‐Hwang Teo, Jia Wern Pan · 2023 · Breast Cancer Research
  97. Mutagenic and carcinogenic polycyclic aromatic hydrocarbons (PAHs) in food – occurrence, human health effects, and assessment methods of exposure
    Maciej Maciejczyk, Krystyna Tyrpień-Golder, Beata Janoszka, Beata Gierat, Roksana Muzyka · 2023 · Environmental Medicine
  98. UPLC-ESI-MS/MS-based widely targeted metabolomics reveals differences in metabolite composition among four Ganoderma species
    Liu Wei-Ye, Guo Hong-Bo, RUI-HENG YANG, Xu Ai-Guo, Jiachen Zhao, Yang Zhao-Qian, Han Wen-Jun, Yu Xiao-Dan · 2024 · Frontiers in Nutrition
  99. Study of apoptosis-related interactions in colorectal cancer
    Himanshu Arora, Rehana Qureshi, M. Moshahid A. Rizvi, Sharad Shrivastava, Mordhwaj Singh Parihar · 2016 · Tumor Biology
  100. TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer
    Daniel Botelho Costa · 2018 · Annals of Oncology